Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Biofouling ; 33(9): 741-754, 2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28899232

RESUMEN

The tough, hydrogel glue produced by the slug Arion subfuscus achieves impressive performance through metal-based, protein cross-links. The primary sequence of these proteins was determined through transcriptome sequencing and proteome analysis by tandem mass spectrometry. The main proteins that correlate with adhesive function are a group of 11 small, highly abundant lectin-like proteins. These proteins matched the ligand-binding C-lectin, C1q or H-lectin domains. The variety of different lectin-like proteins and their potential for oligomerization suggests that they function as versatile and potent cross-linkers. In addition, the glue contains five matrilin-like proteins that are rich in von Willebrand factor A (VWA) and EGF domains. Both C-lectins and VWA domains are known to bind to ligands using divalent cations. These findings are consistent with the double network mechanism proposed for slug glue, with divalent ions serving as sacrificial bonds to dissipate energy.


Asunto(s)
Adhesivos/química , Complemento C1q/análisis , Gastrópodos/química , Lectinas/análisis , ARN/química , Factor de von Willebrand/análisis , Secuencia de Aminoácidos , Animales , Complemento C1q/metabolismo , Electroforesis en Gel de Poliacrilamida , Gastrópodos/genética , Gastrópodos/metabolismo , Geles/química , Humanos , Lectinas/metabolismo , Ligandos , Factor de von Willebrand/metabolismo
2.
Mol Genet Metab Rep ; 24: 100603, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32489881

RESUMEN

We present Boston Children's Hospital's clinic model for pegvaliase therapy in adults with phenylketonuria (PKU) and clinical outcomes in 46 patients over the first 1.5 years of commercial therapy. Approximately 70% (18/26) of patients starting pegvaliase achieved blood phenylalanine (Phe) <360 µmol/L, with an average of a 68 ± 24% decrease in blood Phe from baseline. All patients experienced at least minor side effects, but in most, management of the side effects allowed for treatment to continue.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA